HARROW HEALTH, INC. (29)

Browse by Contract Category

Contracts

Loan and Security Agreement, dated September 1, 2021, by and between the Company and Melt Pharmaceuticals, Inc (Filed With SEC on September 2, 2021)
License and Supply Agreement, dated as of July 25, 2021, by and between the Company and Sintetica, S.A (Filed With SEC on August 10, 2021)
First Amendment to Commercial Alliance Agreement between Eyepoint Pharmaceuticals, Inc. and ImprimisRx, LLC dated November 13, 2020 (Filed With SEC on March 8, 2021)
Consulting Agreement dated July 1, 2020 between Visionology, Inc. and Andrew R. Boll (Filed With SEC on March 8, 2021)
Underwriting Agreement, dated as of June 14, 2021, by and among the Company and B. Riley Securities, Inc., as representative of the several underwriters named therein (Filed With SEC on June 17, 2021)
Securities Purchase Agreement, dated as of May 5, 2021, by and between the Company and B. Riley Securities, Inc (Filed With SEC on May 5, 2021)
First Supplemental Indenture, dated as of April 20, 2021, by and between the Company and U.S. Bank National Association, as Trustee (Filed With SEC on April 20, 2021)
Indenture, dated as of April 20, 2021, by and between the Company and U.S. Bank National Association, as Trustee (Filed With SEC on April 20, 2021)
Underwriting Agreement, dated as of April 15, 2021, by and between the Company and B. Riley Securities, Inc., as representative of the several underwriters named therein (Filed With SEC on April 20, 2021)
Underwriting Agreement, dated as of April 8, 2021, by and among Harrow Health, Inc., Eton Pharmaceuticals, Inc. and National Securities Corporation (Filed With SEC on April 8, 2021)
Consulting Agreement dated July 1, 2020 between Visionology, Inc. and Mark L. Baum (Filed With SEC on March 8, 2021)
Description of the Companys Securities (Filed With SEC on March 8, 2021)
Commercial Alliance Agreement between Eyepoint Pharmaceuticals, Inc. and ImprimisRx, LLC dated August 1, 2020 (Filed With SEC on November 9, 2020)
Business Loan Agreement with Renasant Bank pursuant to the Paycheck Protection Program, dated April 27, 2020 (Filed With SEC on August 10, 2020)
Consulting Agreement dated February 13, 2020 between Stowe Pharmaceuticals, Inc. and John P. Saharek (Filed With SEC on March 13, 2020)
Consulting Agreement dated February 13, 2020 between Stowe Pharmaceuticals, Inc. and Andrew R. Boll (Filed With SEC on March 13, 2020)
Consulting Agreement dated February 13, 2020 between Stowe Pharmaceuticals, Inc. and Mark L. Baum (Filed With SEC on March 13, 2020)
Description of the Companys Securities (Filed With SEC on March 13, 2020)
License Agreement, dated July 29, 2019, among Stowe Pharmaceuticals, Inc., TGV-Health, LLC and TGV-Ophthalnix, LLC (Filed With SEC on November 13, 2019)
License Agreement, dated July 28, 2019, among Mayfield Pharmaceuticals, Inc., TGV-Health, LLC and TGV-Gyneconix, LLC (Filed With SEC on November 13, 2019)
Loan Agreement, dated July 26, 2019, by and between Park Compounding, Inc. and Noice Rx, LLC (Filed With SEC on November 13, 2019)
Asset Purchase Agreement, dated July 26, 2019, by and between Park Compounding, Inc. and Noice Rx, LLC (Filed With SEC on November 13, 2019)
Consulting Agreement dated June 3, 2019 between Mayfield Pharmaceuticals, Inc. and John P. Saharek (Filed With SEC on August 14, 2019)
Consulting Agreement dated June 3, 2019 between Mayfield Pharmaceuticals, Inc. and Mark L. Baum (Filed With SEC on August 14, 2019)
Consulting Agreement dated June 3, 2019 between Mayfield Pharmaceuticals, Inc. and Andrew R. Boll (Filed With SEC on August 14, 2019)
Joinder and Amendment to Loan and Security Agreement, dated May 24, 2019, by and between Harrow Health, Inc., each of its wholly-owned subsidiaries and SWK Funding LLC (Filed With SEC on May 29, 2019)
Asset Purchase Agreement dated February 1, 2019 between Harrow Health, Inc. and Mayfield Pharmaceuticals, Inc (Filed With SEC on May 9, 2019)
Asset Purchase Agreement dated February 1, 2019 between Harrow Health, Inc. and Elle Pharmaceuticals, Inc (Filed With SEC on May 9, 2019)
Asset Purchase Agreement dated December 11, 2018 between Imprimis Pharmaceuticals, Inc. and Melt Pharmaceuticals, Inc (Filed With SEC on February 5, 2019)